54.73
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bio Techne Corp stock is traded at $54.73, with a volume of 2.88M.
It is down -5.16% in the last 24 hours and up +6.38% over the past month.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$57.71
Open:
$56.73
24h Volume:
2.88M
Relative Volume:
1.25
Market Cap:
$8.58B
Revenue:
$1.17B
Net Income/Loss:
$150.71M
P/E Ratio:
58.22
EPS:
0.94
Net Cash Flow:
$245.03M
1W Performance:
-6.40%
1M Performance:
+6.38%
6M Performance:
-25.59%
1Y Performance:
-32.92%
Bio Techne Corp Stock (TECH) Company Profile
Name
Bio Techne Corp
Sector
Industry
Phone
(612) 379-8854
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TECH
Bio Techne Corp
|
54.73 | 9.05B | 1.17B | 150.71M | 245.03M | 0.94 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-22-25 | Resumed | Stephens | Overweight |
Jul-09-25 | Initiated | TD Cowen | Buy |
May-30-25 | Initiated | Wells Fargo | Overweight |
Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
Mar-18-25 | Initiated | Evercore ISI | Outperform |
Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
May-22-24 | Downgrade | Citigroup | Buy → Neutral |
Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
Feb-02-24 | Downgrade | Stifel | Buy → Hold |
Dec-07-23 | Initiated | UBS | Buy |
Aug-28-23 | Initiated | William Blair | Outperform |
Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Dec-14-22 | Initiated | Deutsche Bank | Buy |
Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
Aug-25-22 | Initiated | Credit Suisse | Outperform |
Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
Feb-23-21 | Upgrade | Stifel | Hold → Buy |
Jan-25-21 | Reiterated | The Benchmark Company | Buy |
Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
Sep-30-20 | Initiated | Atlantic Equities | Overweight |
Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
May-27-20 | Downgrade | Stifel | Buy → Hold |
May-14-20 | Initiated | The Benchmark Company | Buy |
Jan-08-20 | Resumed | Stephens | Overweight |
Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
Jan-07-20 | Initiated | Citigroup | Neutral |
Nov-15-19 | Initiated | Stifel | Buy |
Jul-02-19 | Upgrade | Janney | Neutral → Buy |
Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
Oct-17-18 | Initiated | Goldman | Neutral |
Jun-15-18 | Initiated | Argus | Buy |
Jul-13-17 | Initiated | Wells Fargo | Market Perform |
Feb-09-17 | Initiated | Citigroup | Buy |
Jan-18-17 | Initiated | Deutsche Bank | Buy |
Nov-10-16 | Resumed | Leerink Partners | Outperform |
Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio Techne Corp Stock (TECH) Latest News
Promising Long-Term Growth for Bio-Techne Amidst Current Challenges: A Buy Recommendation by Kyle Boucher - TipRanks
Will Bio Techne Corporation stock benefit from interest rate changesProfit Target Stock Opportunity Monitor Activated - metal.it
Momentum Screeners Rank Bio Techne Corporation in Top 5 TodayReal-Time Trade Insights Spark Market Reactions - metal.it
How many analysts rate Bio Techne Corporation as a “Buy”Discover the fastest growing stocks today - jammulinksnews.com
When is Bio Techne Corporation stock expected to show significant growthUnlock real-time stock alerts for quick profits - jammulinksnews.com
How strong is Bio Techne Corporation company’s balance sheetSuperior profit margins - jammulinksnews.com
Bio-Techne Corporation (TECH) Gets Initiated With a New Buy Rating at TD Cowen - Insider Monkey
What makes Bio Techne Corporation stock price move sharplyAchieve rapid capital gains with smart investing - jammulinksnews.com
Is Bio Techne Corporation stock overvalued or undervaluedDiscover stocks with explosive upside potential - jammulinksnews.com
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH) - Yahoo Finance
Bio-Techne’s Quarterly Earnings Preview: What You Need to Know - MSN
10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey
Bio-Techne Corporation (TECH): A Bull Case Theory - Yahoo Finance
What analysts say about Bio Techne Corporation stockTriple returns potential - jammulinksnews.com
Bio-Techne (TECH) Stock Is Up, What You Need To Know - Yahoo Finance
Bio Techne Corporation Stock Analysis and ForecastFree Investment Community - Autocar Professional
Bio-Techne Corporation shares rise 1.99% after-hours as US stocks close higher. - AInvest
Bio-Techne Corp. stock underperforms Monday when compared to competitors - MarketWatch
Envestnet Asset Management Inc. Sells 66,478 Shares of Bio-Techne Corp (NASDAQ:TECH) - Defense World
Bio-Techne’s Quarterly Earnings Preview: What You Need To Know - Barchart.com
Bio-Techne Schedules Q4 2025 Earnings Call: Full Fiscal Year Results Coming August 6 - Stock Titan
Bio-Techne to distribute Spear Bio’s ultrasensitive immunoassays - Yahoo Finance
Bio-Techne Corp (NASDAQ:TECH) Stake Lessened by M&T Bank Corp - Defense World
Analysts Set Bio-Techne Corp (NASDAQ:TECH) Price Target at $70.00 - Defense World
Why Bio Techne Corporation stock attracts strong analyst attentionProfitable Yet Secure Picks - Newser
How Bio Techne Corporation stock performs during market volatilityFree Expert-Led Investment Training - Newser
Here’s Headwaters Capital Management’s Investment Thesis for Bio-Techne (TECH) - Yahoo Finance
Spear Bio partners with Bio-Techne to expand ultrasensitive assay access By Investing.com - Investing.com South Africa
Spear Bio partners with Bio-Techne to expand ultrasensitive assay access - Investing.com
Bio-Techne Secures 1000x More Sensitive Biomarker Detection Technology in Major Neuroscience Partnership - Stock Titan
Bio-Techne (TECH) Partners with Spear Bio for Advanced Biomarker Detection | TECH Stock News - GuruFocus
Revolutionary Alzheimer's Biomarker Detection: Bio-Techne's New Platform Achieves 1000x Higher Sensitivity - Stock Titan
Bio-techne’s technology supports FDA approval of rare skin disorder therapy - Investing.com
Bio-Techne's Simple Western Enables Breakthrough FDA Approval for Rare Skin Disease Gene Therapy - Stock Titan
Teacher Retirement System of Texas Makes New Investment in Bio-Techne Corp (NASDAQ:TECH) - Defense World
Bio-Techne Corp (NASDAQ:TECH) Shares Sold by Principal Financial Group Inc. - Defense World
Teacher Retirement System of Texas Acquires New Holdings in Bio-Techne Corp (NASDAQ:TECH) - Defense World
Scotiabank Has Lowered Expectations for Bio-Techne (NASDAQ:TECH) Stock Price - Defense World
Scotiabank Maintains Buy Rating for Bio-Techne with $75 Price Target - AInvest
Bio-Techne stock price target lowered to $75 by Scotiabank - Investing.com Canada
TD Cowen Begins Coverage on Bio-Techne (NASDAQ:TECH) - Defense World
Minnesota's highest-paid CEOs made 7% more, with highest paid making $59.4M - Star Tribune
Assessing Bio-Techne: Insights From 7 Financial Analysts - Benzinga
Bio-Techne (TECH) Receives Buy Rating with $65 Price Target from TD Cowen | TECH Stock News - GuruFocus
Bio-Techne (TECH): TD Cowen Initiates Coverage with Buy Rating | - GuruFocus
Vontobel Holding Ltd. Decreases Stake in Bio-Techne Corp (NASDAQ:TECH) - Defense World
5 Revealing Analyst Questions From Bio-Techne’s Q1 Earnings Call - Yahoo Finance
Bio-Techne Corp. stock outperforms competitors on strong trading day - MarketWatch
GAMMA Investing LLC Cuts Stake in Bio-Techne Corp (NASDAQ:TECH) - Defense World
Amalgamated Bank Purchases 222 Shares of Bio-Techne Corp (NASDAQ:TECH) - Defense World
Is There Now An Opportunity In Bio-Techne Corporation (NASDAQ:TECH)? - Yahoo Finance
Bio Techne Corp Stock (TECH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):